Literature DB >> 6697426

Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia.

H D Preisler, T Gessner, N Azarnia, W Bolanowska, J Epstein, A P Early, P D'Arrigo, R Vogler, L Winton, P Chervenik.   

Abstract

Plasma adriamycin and adriamycinol levels were measured in 45 patients with acute nonlymphocytic leukemia 3 h after the drug was administered. A wide range of levels as found. Plasma levels increased after the administration of each of the three daily doses of the drug. High plasma levels were associated with both death during remission induction therapy and, for patients who entered remission, long remissions.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6697426     DOI： 10.1007/bf00254604

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  15 in total

1.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

2.  Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay.

Authors:  N R Bachur; C E Riggs; M R Green; J J Langone; H Van Vunakis; L Levine
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

3.  Effects of prior therapy on plasma levels of adriamycin during subsequent therapy.

Authors:  T Gessner; J Robert; W Bolanowska; B Hoerni; M Durand; H Preisler; J Rustum
Journal:  J Med       Date:  1981

4.  Growth of human acute myeloblastic leukemic (aml) cells in vitro.

Authors:  H D Preisler; G Christoff; C Epstein
Journal:  Blut       Date:  1979-01-22

5.  Remission induction in acute nonlymphocytic leukemia: comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin.

Authors:  H Preisler; S Bjornsson; E S Henderson; W Hryniuk; D Higby; A Freeman; C Naeher
Journal:  Med Pediatr Oncol       Date:  1979

6.  Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.

Authors:  H D Preisler; Y Rustum; E S Henderson; S Bjornsson; P J Creaven; D J Higby; A Freeman; S Gailani; C Naeher
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

Review 7.  Treatment failure in AML.

Authors:  H D Preisler
Journal:  Blood Cells       Date:  1982

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.

Authors:  H D Preisler; A Early; W Hryniuk
Journal:  Med Pediatr Oncol       Date:  1981

10.  Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.

Authors:  J K Rees; R M Sandler; J Challener; F G Hayhoe
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640
View more
  19 in total

1.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.

Authors:  Alex Bogason; Angelica L Quartino; Pierre Lafolie; Michèle Masquelier; Mats O Karlsson; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 4.  Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

Authors:  J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Disposition of epirubicin and metabolites with repeated courses to cancer patients.

Authors:  R G Morris; D Kotasek; G Paltridge
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 9.  Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

Authors:  Romano Danesi; Stefano Fogli; Alessandra Gennari; Pierfranco Conte; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Authors:  Alex Bogason; Hasanuzzaman Bhuiyan; Michèle Masquelier; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2009-10-10       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.